Compounded Tirzepatide vs Zepbound: Same Molecule, Different Product

Compounded tirzepatide is meant to be the same active molecule as Zepbound, but it is not the same product. Zepbound is made by Eli Lilly to a formula FDA reviewed and approved; a compounded vial is mixed by a pharmacy from tirzepatide it buys, and FDA does not review compounded drugs for safety, effectiveness or quality before they are sold.^[3] No trial has tested compounded tirzepatide against Zepbound, so whether a given vial works as well depends on whether it contains what its label says.^[6] Since FDA declared the tirzepatide shortage over in December 2024, routine copies of Zepbound are no longer lawful to compound.^[2]

What compounded tirzepatide is

Compounding is a pharmacy making a medicine for a patient from raw ingredients, instead of dispensing a finished product from a drug company. Compounded tirzepatide is tirzepatide powder, bought by the pharmacy as a bulk active ingredient, dissolved and filled into vials, often with other ingredients added. The pharmacy is either a state-licensed 503A pharmacy filling individual prescriptions or a 503B outsourcing facility that makes larger batches under FDA manufacturing rules.^[2] The difference between the two is explained in 503A vs 503B compounding pharmacies.

“Compounded” does not mean approved. FDA states plainly that a compounded drug carries no FDA approval, and that the agency does not check one for safety, effectiveness or quality before it reaches patients.^[3]

Is it the same molecule as Zepbound?

It is supposed to be. Tirzepatide is a specific peptide: the Zepbound label describes a chain built on the GIP sequence, with two unusual amino acids at positions 2 and 13 and a fatty-acid chain attached at position 20, for a molecular weight of 4,813.53.^[1] A compounded product labeled tirzepatide should contain that same chain. What no one has checked for you is whether it does, how much of it there is, and what else came along with it.

That is the gap between a molecule and a product. Lilly’s tirzepatide is made and tested under an approved application, and the strength and impurity limits are part of what FDA reviewed. A compounder’s bulk tirzepatide comes from a supplier the pharmacy chooses, and the finished vial is not submitted to FDA. For semaglutide, FDA has warned that some compounders used salt forms, semaglutide sodium and semaglutide acetate, which it calls different active ingredients from the approved drug.^[3] FDA’s page does not name a tirzepatide salt. The ingredient line on a compounded vial’s label, and the pharmacy that made it, are what tell you which form is inside. What else to look for on that label is covered in what is in a compounded GLP-1 vial.

Zepbound ingredients from section 11 of its label.^[1] Compounded additions from a survey of compounding websites and a secret-shopper study of clinics.^[6][8]

What is added to compounded tirzepatide, and why it matters

Much of the compounded tirzepatide sold today is not plain tirzepatide. In a survey of compounding websites in early 2025, 48% of compounded semaglutide and tirzepatide products contained the drug mixed with something else: cyanocobalamin (vitamin B12), glycine, niacinamide, docusate or ondansetron. The authors found little justification for adding nutrients to an injection of this kind.^[6] Researchers posing as patients contacted 75 clinics and med spas selling weight-loss drugs in two states, Oklahoma and West Virginia, between August and October 2025. The study found that 56% offered compounded GLP-1 drugs combined with B vitamins. Four of 21 supplier facilities were not licensed for sterile compounding.^[8]

The additions are partly a legal strategy: with the shortage over, compounders can only sell products that differ from the approved one.^[6] They also change the chemistry. Lilly scientists tested compounded tirzepatide with B12 bought on the US market and reported an impurity formed by a reaction between tirzepatide and certain forms of B12, present at substantial levels; its effect on patients is unknown.^[7] That study was written entirely by employees of the company that sells Zepbound, and it has not been repeated by an independent lab. Even so, it shows the kind of problem a combination can create when nobody has to test it before sale.

Can compounded tirzepatide still be sold legally?

During the shortage, pharmacies could compound copies of Zepbound and Mounjaro because the brand was not available. FDA first declared the tirzepatide injection shortage resolved on October 2, 2024. After a lawsuit, that decision went back to the agency for another look, and FDA confirmed it on December 19, 2024. Under that decision, shortage-based compounding had to wind down by February 18, 2025 at state-licensed 503A pharmacies, and by March 19, 2025 at 503B outsourcing facilities. A court refused to block that decision on March 5, 2025.^[2] As of FDA’s April 2026 update, tirzepatide is on neither the drug shortage list nor the 503B bulks list.^[2]

Two paths are left, and both are narrow. A 503A pharmacy may still compound tirzepatide for a specific patient, but under federal law it may not regularly or in large amounts compound what are essentially copies of a commercially available drug.^[2] That is why compounders now point to a different strength, an added ingredient or a different form. For 503B outsourcing facilities, FDA proposed on April 30, 2026 to keep tirzepatide off the list of bulk substances they may use, saying outsourcing facilities cannot lawfully compound from bulk when an approved drug is available.^[4] The comment period was extended to July 30, 2026, and no final decision had been published as of October 31, 2026.^[5] Which GLP-1 drugs can be compounded, and on what basis, is covered in which GLP-1 can be compounded.

Does compounded tirzepatide work?

If the vial contains the right amount of real tirzepatide, it should act the way tirzepatide does, because the drug’s effect comes from the molecule. The evidence for that effect comes from Zepbound’s trials: in SURMOUNT-1, adults without diabetes lost 15.0% to 20.9% of their weight over 72 weeks, depending on dose, against 3.1% on placebo.^[10] How the molecule produces that loss is covered in how Zepbound works.

No randomized trial has tested a compounded tirzepatide product, and none has compared one with Zepbound. The closest thing published is a retrospective review by a telehealth weight-loss program of 1,166 patients who stayed on its protocol for at least a year, using either compounded or brand tirzepatide. Those patients lost 22.74% of their weight on average at 52 weeks.^[9] That figure counts only people who completed a year, has no comparison group, does not separate compounded from brand, and was published by the program that sells the treatment. It cannot tell you whether compounded tirzepatide works as well as Zepbound.

What can go wrong is a dose that is not what the label says. FDA has received more than 730 reports of adverse events with compounded tirzepatide as of May 31, 2026, and it notes that such reports are voluntary and incomplete.^[3] A vial that is under strength would look like a drug that does not work; one that is over strength, or that a patient draws up in the wrong number of units, would look like a drug with bad side effects.

How to compare the two if you are deciding

• Ask which pharmacy made the vial and whether it is a 503A pharmacy or a 503B outsourcing facility. A seller that will not say is the clearest warning sign.
• Read the ingredient line. It should say tirzepatide, and list every added ingredient. A product with B12 or other additions is a different product from Zepbound, not a cheaper copy of it.
• Check the concentration in mg per mL and how many units your dose is. Strengths vary between pharmacies, so the same number of units can mean different doses.
• Zepbound itself also comes in single-dose and multi-dose vials, not only pens.^[1] Current cash prices are tracked on the Zepbound drug page.